Physician profile
Hank Ashforth
NPI 1083110423
$2,947.02
in general payments reported to CMS, 2019-2025
25 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,631 · 2022: $315 · 2023: $195 · 2024: $174 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,301.30 | 2021 | |
| Novo Nordisk INC | $282.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $213.06 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $188.31 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $174.33 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.83 | 2021-2023 | Jardiance |
| Amgen INC. | $110.67 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $104.43 | 2021-2025 | |
| Lilly USA, LLC | $95.29 | 2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $42.80 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.65 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.35 | 2022-2023 | |
| Lundbeck LLC | $20.03 | 2024 | Rexulti |
| Abbott Laboratories | $17.32 | 2025 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $16.86 | 2021 | |
| Bausch Health US, LLC | $16.56 | 2025 | Wellbutrin |
| Scilex Pharmaceuticals INC. | $14.79 | 2021 | |
| Amarin Pharma, INC. | $14.62 | 2021 | |
| Currax Pharmaceuticals LLC | $14.47 | 2025 | Contrave |
| Esperion Therapeutics, INC. | $14.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.06 | 2021 | |
| Dynavax Technologies Corporation | $13.27 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hank Ashforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.